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EpidemiologyBackground: The incidence of infective endocarditis (IE) has increased in recent decades. Societal lock-
down including reorganization of the healthcare system during the COVID-19 pandemic may influence
the incidence of IE. This study sets out to investigate the incidence of IE during the Danish national lock-
down.
Methods: In this nationwide cohort study, patients admitted with IE in either one of two periods A) A
combined period of 1 January to 7 May for 2018 and 2019, or B) 1 January to 6 May 2020, were identified
using Danish nationwide registries. Weekly incidence rates of IE admissions for the 2018/2019-period
and 2020-period were computed and incidence rate ratios (IRR) for 2020-incidence vs 2018/2019-
incidence were calculated using Poisson regression analysis.
Results: In total, 208 (67.3% men, median age 74.1 years) and 429 (64.1% men, median age 72.7 years)
patients were admitted with IE in 2020 and 2018/2019, respectively. No significant difference in inci-
dence rates were found comparing the 2020-period and 2018/2019-period (IRR: 0.96 (95% CI: 0.82–
1.14). The overall incidence rate pre-lockdown (week 1–10: 1 January to 11 March 2020) was 14.2 IE
cases per 100,000 person years (95% CI: 12.0–16.9) as compared with 11.4 IE cases per 100,000 person
years (95% CI: 9.1–14.1) during lockdown (week 11–18: 12 March to 6 May 2020) corresponding to an
IRR of 0.80 (95% CI: 0.60–1.06) and thus no significant difference pre- versus post-lockdown.
Conclusion: In this nationwide cohort study, no significant difference in the incidence of IE admissions
during the national lockdown due to the COVID-19 pandemic was found.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic, caused by
the novel acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has entailed a dramatic impact on global health pushing health
care systems to the limit of breakdown. COVID-19 may cause vari-
able symptoms from mild upper respiratory disease to severe
lower respiratory disease potentially complicated by acute respira-tory distress syndrome, sepsis, and multi-organ failure [1,2]. Due to
high infection pressures and risk of severe outcomes, international
efforts including social distancing, societal lockdown, and reorga-
nization of healthcare systems optimized for handling COVID-19
have been imposed to prevent spread of the virus. In Denmark,
the first confirmed COVID-19 positive case was identified on 27
February 2020 and national lockdownwas announced on 11March
2020 [3].
Infective endocarditis (IE) is associated with high morbidity and
mortality caused by mainly gram positive cocci [4–8]. Recent stud-
ies have reported an increasing incidence of IE during the past two
decades [9–12]. First, reorganization of the healthcare system dur-
ing lockdown includes postponing elective procedures entailing
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acquired bacteremia and thus potentially a declined incidence of
IE. Second, increased focus on sanitation and societal lockdown
are preventive measures against COVID-19 but presumably also
against other infectious diseases even though mode of transmis-
sion differs. A decline in influenza rates during societal lockdowns
have been reported [13]. Finally, in fear of COVID-19 infection or
overloading the health care system, some patients may have
refrained from consulting a physician despite a display of symp-
toms. Thus, one could hypothesize a decline in the incidence
and/or diagnosis of IE during lockdown. During the COVID-19 pan-
demic plural studies have shown a decline within admissions with
acute coronary syndrome, whether the same pattern is seen for IE
is yet unknown [14–16].
In order to enlighten the impact of the COVID-19 pandemic on
IE, we set out to investigate the incidence of IE during the Danish
national lockdown.2. Methods
2.1. Data sources
All Danish citizens are assigned a permanent unique identifica-
tion number allowing accurate linkage of nationwide administra-
tive registries at an individual level. For this study, data from the
following nationwide administrative registries were obtained: 1)
The Danish National Patient Registry, which holds information on
all hospital admissions and outpatient contacts according to the
International Classification of Diseases (ICD) 8th and 10th revision
and surgical procedures according to the NOMESCO Classification
of Surgical Procedures (NCSP) [17]. 2) The Danish National Pre-
scription Registry, which contains information until 29 February
2020 on dispensing date, strength, and quantity on all claimed
drug prescriptions in Denmark [18]. 3) The Danish Civil Registra-
tion System, which holds data on birth date, sex, and vital status
(i.e. whether a person is alive and resident in Denmark, disap-
peared [persons whose residence is unknown to Danish authori-
ties], emigrated, or dead - along with the date of these events)
[19]. The Danish registries are validated and of high quality as
described in detail previously [17–21].
2.2. Danish health care system during the COVID-19 pandemic
The Danish health care system, funded by taxes, provides equal
access to healthcare services and welfare benefits for all residents
regardless of socioeconomic or insurance status. In Denmark, the
first incidence of COVID-19 was confirmed on 27 February 2020,
the Danish government implemented national lockdown on 11
March 2020, and the borders were closed on 18 March 2020. The
Danish healthcare system was reorganized and optimized for han-
dling COVID-19; outpatient visits were cancelled or converted to
telemedicine, elective procedures and dental appointments were
postponed, and furthermore, emergency rooms, test centers, and
intensive care units were adjusted to adapt to COVID-19 patients.
On 6 April 2020, the Danish Government announced the first step
of controlled reopening of the Danish society.
2.3. Study population
The study cohort comprised all Danish citizens in either one of
two periods: 1) A combined period of 1 January 2018 to 7 May
2018 and 1 January 2019 to 7 May 2019, or 2) 1 January 2020 to
6 May 2020. Due to leap year in 2020, the study dates differ
between the study periods, thus, the total follow-up time was
maximum 126 days for each period. A combined period from2
2018 and 2019 were used in order to get reliable information about
the historic incidence of IE in similar times of the year and thereby
reduce the risk of random variation. Patients admitted with IE prior
to the abovementioned study periods were excluded. Fig. 1 depicts
a flowchart of the patient selection.
2.4. Covariates
Demographic data (age and sex) were obtained from the Danish
Civil Registration System. Comorbidities were assessed from the
National Patient Registry as in-hospital and out-patient diagnoses
any time prior to IE admission. The following comorbidities were
assessed: stroke, atrial fibrillation, peripheral vascular disease,
heart failure, chronic renal failure, dialysis, acute renal failure, dia-
betes, chronic obstructive pulmonary disease, liver disease,
rheumatologic disease, malignancy, presence of a cardiac implan-
table electronic device (defined as an implantation of a pacemaker
or implantable cardioverter), and presence of a prosthetic heart
valve (Supplementary Table 1 presents ICD-8, ICD-10, and NCSP
codes). Concomitant pharmacotherapy was assessed from the Dan-
ish National Prescription Registry as a filled prescription within
one year prior to IE admission (Supplementary Table 1 presents
ATC codes). Hypertension was defined using claimed antihyperten-
sive drug prescriptions as described previously [22,23].
2.5. Outcomes
The primary outcome was first-time admission with IE. IE was
defined from the following ICD-10 codes: I33 (acute and sub-
acute endocarditis), I38 (endocarditis, valve unspecified), and
I398 (endocarditis unspecified). Only patients
hospitalized  14 days or those who died earlier were included.
Patients were considered hospitalized during transfers between
departments and hospitals if a period of discharge was less than
24 h. Using these criteria, the diagnosis of IE in the Danish National
Patient Registry has previously been validated with a positive pre-
dictive value of 90% [24]. Persons included in the study were fol-
lowed from date of entry until occurrence of the outcome of
interest, death, or end of study (7 May 2018, 7 May 2019, or 6
May 2020, respectively), whichever came first. Concomitant
COVID-19 infection was defined from the following ICD-10 codes:
B342A, B972, and B972A.
2.6. Statistics
Descriptive characteristics for patients admitted to hospital
with IE were compared between the two study periods: A) 1 Jan-
uary to 7 May 2018/2019, versus B) 1 January to 6 May 2020. Char-
acteristics were reported by use of frequencies and percentages for
categorical variables and medians with 25th-75th percentiles for
continuous variables. The number of IE admissions was compared
between study periods. For the combined study period of 2018 and
2019, the average number of IE admissions were calculated for
comparison with the number of IE admissions in the 2020 study
period and differences between the two periods were analyzed.
Weekly incidence rates were computed as the number of IE admis-
sions per 100,000 person years. Thus, for the computation of inci-
dence rates the study cohort was split in bands of weeks (7 days)
from index date (January 1). Incidence rate ratios with 95% confi-
dence intervals were computed using a Poisson regression analysis
to estimate the relative incidence of IE between the two study peri-
ods for every week (week 1–18).
Further, we investigated the incidence of IE before and after the
lockdown (lock down announcement on 11 March 2020) and two
additional study periods were compared: A) 13 March to 7 May
2018 and 13 March to 7 May 2019, and B) 12 March to 6 May
Fig. 1. Flowchart. The figure shows the selection process for the study population.
Table 1
Baseline characteristics for patients admitted with IE.
1 January to
7 May 2018/
2019 N = 429
1 January to
6 May
2020 N = 208
Demographics
Age (years), median (IQR) 72.7 (62.9–80.2) 74.1 (63.8–80.6)
Male, N (%) 275 (64.1%) 140 (67.3%)
Comorbidities, N (%)
Stroke 49 (11.4%) 19 (9.1%)
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the two periods and differences in IE admissions were assessed.
Moreover, the incidence of IE post-lockdown (12 March to 6 May
2020) was compared with the pre-lockdown period of 2020 (1 Jan-
uary to 11 March 2020) using Poisson regression analysis. Data
management and statistical analyses were performed with SAS sta-
tistical software (SAS 9.4, SAS Institute, Cary, North Carolina, USA)
and R (version 3.6.1, The R Foundation) [12]. The level of statistical
significance was set at 5%.Atrial flutter/fibrillation 103 (24.0%) 57 (27.4%)
Peripheral vascular disease 27 (6.3%) 20 (9.6%)
Chronic heart Failure 64 (14.9%) 36 (17.3%)
Chronic renal failure 69 (16.1%) 29 (13.9%)
Dialysis 40 (9.3%) 20 (9.6%)
Diabetes 106 (24.7%) 41 (19.7%)
COPD 46 (10.7%) 27 (13.0%)
Liver disease 27 (6.3%) 15 (7.2%)
Rheumatologic disease 35 (8.2%) 15 (7.2%)
Malignancy 95 (22.1%) 53 (25.5%)
CIED 80 (18.6%) 34 (16.3%)
Prosthetic heart valve 88 (20.5%) 45 (21.6%)
Hypertension 219 (51.0%) 119 (57.2%)3. Results
In total, 4,611,451, 4,641,357, and 4,662,175 Danish citizens
were identified at 1 January 2018, 1 January 2019, and 1 January
2020, respectively. In the 2018/2019-period, 429 patients were
admitted with first-time IE while 208 patients were admitted in
the 2020-period. Table 1 depicts baseline characteristics for
patients with IE in the two study periods and overall no differences
in sex, age, or comorbidities were found.Pharmacotherapy, N (%)
Beta blockers 169 (39.4%) 92 (44.2%)
Calcium channel blockers 99 (23.1%) 63 (30.3%)
RASi 182 (42.4%) 95 (45.7%)
Loop-diuretics 158 (36.8%) 87 (41.8%)
Statins 190 (44.3%) 92 (44.2%)
ASA 109 (25.4%) 38 (18.3%)
ADPi 52 (12.1%) 26 (12.5%)
OAC 147 (34.3%) 81 (38.9%)
IE: infective endocarditis, IQR: interquartile range, COPD: chronic obstructive pul-
monary disease, CIED: cardiac implantable electronic device, RASi: renin angio-
tensin system inhibitor, ASA: aspirin, ADPi: adenosine-di-phosphate inhibitor, OAC:
oral anticoagulant therapy3.1. Comparison of IE admissions; 2020 versus 2018/2019
Comparing the average number of IE admissions in the
2018/2019-period with the 2020-period, we identified a 3.0%
decline. Fig. 2 depicts incidence rates with 95% CI bands per week
in 2020 as compared with 2018/2019 and a slight though non-
significant decline was seen after lockdown in 2020 when com-
pared with the average in 2018/2019. The overall incidence rate
in week 1–18 was 13.5 IE cases per 100,000 PY (95% CI: 12.3–
14.8) in 2018/2019 and 13.0 IE cases per 100,000 PY (95% CI:
11.3–14.8) in 2020. In regression analysis no significant differences
were seen between 2018/2019 and 2020 (IRR: 0.96 (95% CI: 0.82–
1.14), Fig. 3 depicts the incidence rate ratios per week in 2020 com-
pared with 2018/2019). Supplementary figure 1 depicts the weekly
number of IE admissions in the two study periods.3.2. Lockdown period in 2020
From 13 March to 7 May 2018/2019 an average of 93.5 patients
were admitted with IE whereas 81.0 patients were admitted from
12 March to 6 May 2020, corresponding to a 13.4% decline. Table 2
depicts baseline characteristics for patients with IE in the two
study periods before and after announcement of lockdown and3
overall no differences in sex, age, or comorbidities were found.
From week 1–10 2020 (1 January to 11 March), the incidence rate
was 14.2 IE cases per 100,000 PY (95% CI 12.0–16.9) in 2020 as
compared with 13.7 IE cases per 100,000 PY (95% CI 12.0–15.5)
in the corresponding period in 2018/2019. The overall incidence
during lockdown (week 11–18: 12 March to 6 May 2020) was
11.4 IE cases per 100,000 PY (95% CI 9.1–14.1) whereas it was
13.2 IE cases per 100,000 PY (95% CI 11.5–15.3) in the correspond-
ing period in 2018/2019. The IRR was 0.80 (95% CI: 0.60–1.06) for
week 11–18 2020 as compared with week 1–10 2020. Hence, no
significant differences pre- versus post-lockdown was found. In
Fig. 2. Incidence rates of IE admissions with 95% CI bands in 2020 versus 2018/2019. The figure shows the incidence rates in 2020 as compared with 2018/2019. IE: Infective
endocarditis.
Fig. 3. Incidence rate ratios of IE admissions in 2020 versus 2018/2019. The figure shows the incidence rate ratios per week (1–18) in 2020 as compared with week 1–18 in
2018/2019. IE: Infective endocarditis.
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concomitant COVID-19 infection. Because of the low number of
patients, no further information can be given on these cases due
to the rules on anonymity by Statistics Denmark.4
4. Discussion
In this Danish nationwide cohort study, we investigated the
incidence of IE during the Danish national lockdown. The main
Table 2
Baseline characteristics for patients admitted with IE.
1 January to 11 March
2018/2019 N = 242
13 March to 7 May
2018/2019 N = 187
1 January to 11 March
2020 N = 127
12 March to 6 May
2020 N = 81
Demographics
Age (years), median (IQR) 71.1 (61.0–79.5) 74.4 (65.5–81.8) 74.6 (62.7–80.6) 73.8 (63.9–80.8)
Male, N (%) 152 (62.8%) 123 (65.8%) 85 (66.9) 55 (67.9%)
Comorbidities, N (%)
Stroke 28 (11.6%) 21 (11.2%) 15 (11.8%) 4 (4.9%)
Atrial flutter/fibrillation 52 (21.5%) 51 (27.3%) 35 (27.6%) 22 (27.2%)
Peripheral vascular disease 16 (6.6%) 11 (5.9%) 11 (8.7%) 9 (11.1%)
Chronic heart failure 35 (14.5%) 29 (15.5%) 25 (19.7%) 11 (13.6%)
Chronic renal failure 39 (16.1%) 30 (16.0%) 21 (16.5%) 8 (9.9%)
Dialysis 24 (9.9%) 16 (8.6%) 16 (12.6%) 4 (4.9%)
Diabetes 59 (24.4%) 47 (25.1%) 26 (20.5%) 15 (18.5%)
COPD 27 (11.2%) 19 (10.2%) 13 (10.2%) 14 (17.3%)
Liver disease 15 (6.2%) 12 (6.4%) 11 (8.7%) 4 (4.9%)
Rheumatologic disease 21 (8.7%) 14 (7.5%) 5 (3.9%) 10 (12.3%)
Malignancy 44 (18.2%) 51 (27.3%) 32 (25.2%) 21 (25.9%)
CIED 42 (17.4%) 38 (20.4%) 19 (15.0%) 15 (18.5%)
Prosthetic heart valve 54 (22.3%) 34 (18.2%) 25 (19.7%) 20 (24.7%)
Hypertension 122 (50.4%) 97 (51.9%) 74 (58.3%) 45 (55.6%)
Pharmacotherapy, N (%)
Beta blockers 91 (37.6%) 78 (41.7%) 60 (47.2%) 32 (39.5%)
Calcium channel blockers 56 (23.1%) 43 (23.0%) 37 (29.1%) 26 (32.1%)
RASi 104 (43.0%) 78 (41.7%) 56 (44.1%) 39 (48.1%)
Loop-diuretics 87 (36.0%) 71 (38.0%) 56 (44.1%) 31 (38.3%)
Statins 103 (42.6%) 87 (46.5%) 60 (47.2%) 32 (39.5%)
ASA 63 (26.0%) 46 (24.6%) 23 (18.1%) 15 (18.5%)
ADPi 28 (11.6%) 24 (12.8%) 18 (14.2%) 8 (9.9%)
OAC 74 (30.6%) 73 (39.9%) 48 (37.8%) 33 (40.7%)
IE: infective endocarditis, IQR: interquartile range, COPD: chronic obstructive pulmonary disease, CIED: cardiac implantable electronic device, RASi: renin angiotensin system
inhibitor, ASA: aspirin, ADPi: adenosine-di-phosphate inhibitor, OAC: oral anticoagulant therapy
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the incidence of IE during the national lockdown as compared with
the corresponding period in 2018/2019.
In recent studies, the annual incidence of IE have been found to
range from 3 to 7 per 100,000 person-years [9,6] Patients with
prior IE, prosthetic heart valve, or a cyanotic congenial heart dis-
ease are considered in high risk of IE, whereas patients with heart
valve disorder, cardiac implantable electronic devices, or hyper-
trophic cardiomyopathy are considered in moderate risk of IE
[5,25,26]. Correspondingly, a number of diseases and conditions
has been associated with increased susceptibility to and severe
course of COVID-19; in Denmark, it concerns elderly (>65 years),
persons with chronic diseases including cardiovascular disease,
immune-compromised patients, and children with sequalae of pre-
maturity [27]. Thus, there is an overlap of risk factors among
patients in risk of IE and COVID-19. In Denmark, emphasis has
been placed on recommendations for persons in increased risk of
COVID-19, including intensified hygienic precautions. Cutaneous
hygiene is the general advice for those in moderate- and high-
risk of IE[5], consequently, increased awareness in the general pop-
ulation and among vulnerable persons may potentially ameliorate
the effort of precautions and one may have expected a decline in
the admission rate of IE.
Elective surgical and dental procedures were cancelled or
postponed during lockdown. It is well known that dental
procedures are at-risk procedures for those in high-risk of IE, and
antibiotic prophylaxis is recommended, whereas antibiotic
prophylaxis routinely is not recommended for respiratory tract-,
gastrointestinal-, urogenital-, skin-, or soft tissue procedures [5].
Therefore, if there were room for improvement concerning various
procedures, a decline in the incidence of IE during lockdown could
be expected. Fewer elective procedures would cause fewer hospi-
talizations and potentially fewer hospital-acquired bacteremia
and hypothetically a declined incidence of IE. Thus, the unaltered
incidence of IE from 2018/2019 to 2020 substantiate the current5
clinical guidelines concerning antibiotic prophylaxis for those at
high-risk of IE. On the other hand, one could speculate that pro-
longed postponement of routine dental check-ups could deterio-
rate dental state and increase the risk of IE – presumably, a
longer lockdown period would be needed in order to clarify this
hypothesis.
Moreover, in fear of COVID-19 infection or overloading the
health care system, some patients may have refrained from con-
sulting a physician despite having symptoms, but fortunately this
seems not to be the case concerning IE. However, a trend towards
a decline in the lockdown period could be interpreted from our
results and the wide confidence intervals could suggest a type
II-error.
Reorganization of the healthcare system including postponing
elective cardiac surgeries may impact patients with IE, as reported
in a recent case report by Hussain et al. on an IE case complicated
by COVID-19 and severe hemorrhages [28]. Further studies are
needed in order to enlighten the course of concomitant IE and
COVID-19 infection. Lockdown has proven to be an effective strat-
egy in slowing down the COVID-19 pandemic with significant
reduction in infection and death rates [29]. However, our study
does not provide evidence of a significant effect of lockdown on
the incidence of IE.
4.1. Strengths and limitations
The main strength of this study is the completeness of data in a
large nationwide cohort. The Danish healthcare registries provide a
unique opportunity for the investigation of a national lockdown
during the COVID-19 pandemic. The accuracy of the data relies
upon the coding in nationwide administrative registries, though
these have been validated previously [30,24]. The diagnosis of IE
has previously been validated with high positive predictive values
[24]. However, the findings in this study should be viewed in the
context of a number of limitations. Due to the relatively low
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ruled out. Further, we were not able to differentiate between the
location of IE (i.e. prosthetic valve, native valve, or cardiac implan-
table electronic devices). In addition, data on microbiology, use of
antibiotic therapy, echocardiographic findings, and other imaging
modalities (e.g. PET-CT) in patients with IE were not available.
The observational nature of this study precludes the assessment
of cause-effect relationships, and the influence of potential con-
founders and thus residual confounding cannot be omitted.
5. Conclusion
In this nationwide cohort study, no significant difference in the
incidence of IE admissions during the national lockdown due to the
COVID-19 pandemic was found as compared to similar periods in
the preceding years and to the pre-lockdown period of 2020.
Funding
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
Declaration of Competing Interest
EHB: None declared
ELF: Previous research funding from Janssen and Janssen and
Bristol-Myers
JHB: None declared
JKP: None declared
ADJ: None declared
FK: None declared
MS: None declared
MP: None declared
KK: None declared
GHG: Research grants from Bayer, Bristol-Myers Squibb, Pfizer,
AstraZeneca and Boehring Ingelheim
CTP: Consultant fees and research funding from Bayer and
Biotronic
LK: None declared
LØ: None declared
Acknowledgments
None
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ijcha.2020.100675.
References
[1] V. Jain, J.-M. Yuan, Predictive symptoms and comorbidities for severe COVID-
19 and intensive care unit admission: a systematic review and meta-analysis,
Int J Public Health 65 (5) (2020) 533–546, https://doi.org/10.1007/s00038-
020-01390-7.
[2] E. Driggin, M.V. Madhavan, B. Bikdeli, T. Chuich, J. Laracy, G. Biondi-Zoccai, T.S.
Brown, C. Der Nigoghossian, D.A. Zidar, J. Haythe, D. Brodie, J.A. Beckman, A.J.
Kirtane, G.W. Stone, H.M. Krumholz, S.A. Parikh, Cardiovascular Considerations
for Patients, Health Care Workers, and Health Systems During the COVID-19
Pandemic, Journal of the American College of Cardiology 75 (18) (2020) 2352–
2371, https://doi.org/10.1016/j.jacc.2020.03.031.
[3] Statens Serum institut, Første dansker testet positiv for COVID-19, (2020) 27–
28. https://www.ssi.dk/aktuelt/nyheder/2020/02_27_foerste-tilfaelde-af-ny-
coronavirus-i-dk.
[4] L. Østergaard, N.E. Bruun, M. Voldstedlund, M. Arpi, C.Ø. Andersen, H.C.
Schønheyder, L. Lemming, F. Rosenvinge, N. Valeur, P. Søgaard, P.S. Andersen,
R. Skov, M. Chen, K. Iversen, S. Gill, T.K. Lauridsen, A. Dahl, L.B. Oestergaard, J.A.
Povlsen, C. Moser, H. Bundgaard, L. Køber, E.L. Fosbøl, Prevalence of infective6
endocarditis in patients with positive blood cultures: a Danish nationwide
study, Eur. Heart J. 40 (39) (2019) 3237–3244, https://doi.org/10.1093/
eurheartj/ehz327.
[5] G. Habib, P. Lancellotti, M.J. Antunes, M.G. Bongiorni, J.-P. Casalta, F. Del Zotti,
R. Dulgheru, G. El Khoury, P.A. Erba, B. Iung, J.M. Miro, B.J. Mulder, E. Plonska-
Gosciniak, S. Price, J. Roos-Hesselink, U. Snygg-Martin, F. Thuny, P. Tornos Mas,
I. Vilacosta, J.L. Zamorano, 2015 ESC Guidelines for the management of
infective endocarditis: The Task Force for the Management of Infective
Endocarditis of the European Society of Cardiology (ESC)Endorsed by:
European Association for Cardio-Thoracic Surgery (EACTS), the European
Association of Nuclear Medicine (EANM), Eur Heart J 36 (44) (2015) 3075–
3128, https://doi.org/10.1093/eurheartj/ehv319.
[6] L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr, I.M. Tleyjeh, M.J. Rybak, B.
Barsic, P.B. Lockhart, M.H. Gewitz, M.E. Levison, A.F. Bolger, J.M. Steckelberg, R.
S. Baltimore, A.M. Fink, P. O’Gara, K.A. Taubert, Infective Endocarditis in Adults:
Diagnosis, Antimicrobial Therapy, and Management of Complications: A
Scientific Statement for Healthcare Professionals From the American Heart
Association, Circulation 132 (15) (2015) 1435–1486, https://doi.org/10.1161/
CIR.0000000000000296.
[7] E. Havers-Borgersen, E.L. Fosbøl, R. Rørth, K. Kragholm, S.L. Kristensen, H.
Bundgaard, N.E. Bruun, L. Østergaard, M. Aslam, N. Valeur, G.H. Gislason, C.
Torp-Pedersen, L. Køber, J.H. Butt, Nursing Home Admission and Initiation of
Domiciliary Care Following Infective Endocarditis, gh 14 (1) (2019) 41, https://
doi.org/10.1016/j.gheart.2019.01.002.
[8] E. Havers-Borgersen, J.H. Butt, L. Østergaard, H. Bundgaard, M. Smerup, N.E.
Bruun, G.H. Gislason, C. Torp-Pedersen, L. Køber, E.L. Fosbøl, Recurrent
infective endocarditis versus first-time infective endocarditis after heart
valve surgery, Clin Res Cardiol 109 (11) (2020) 1342–1351, https://doi.org/
10.1007/s00392-020-01628-7.
[9] P. Erichsen, G.H. Gislason, N.E. Bruun, The increasing incidence of infective
endocarditis in Denmark, 1994–2011, European Journal of Internal Medicine
35 (2016) 95–99, https://doi.org/10.1016/j.ejim.2016.05.021.
[10] C. Olmos, I. Vilacosta, C. Fernández-Pérez, J.L. Bernal, C. Ferrera, D. García-
Arribas, C.N. Pérez-García, J.A. San Román, L. Maroto, C. Macaya, F.J. Elola, The
Evolving Nature of Infective Endocarditis in Spain, Journal of the American
College of Cardiology 70 (22) (2017) 2795–2804, https://doi.org/10.1016/
j.jacc.2017.10.005.
[11] S. Pant, N.J. Patel, A. Deshmukh, H. Golwala, N. Patel, A. Badheka, G.A. Hirsch, J.
L. Mehta, Trends in Infective Endocarditis Incidence, Microbiology, and Valve
Replacement in the United States From 2000 to 2011, Journal of the American
College of Cardiology 65 (19) (2015) 2070–2076, https://doi.org/10.1016/
j.jacc.2015.03.518.
[12] and M.H.T. Mark J Dayer, Simon Jones, Bernard Prendergast, Larry M. Baddour,
Peter B Lockhart, Incidence of infective endocarditis in England, 2000-13: a
secular trend, interrupted time series analysis, Lancet. (2015) 1219–1228.
[13] WHO, Influenza Update N  191, (2013) 1–7.
[14] M.D. et al. Ovidio De Filippo, Reduced Rate of Hospital Admissions for ACS
during Covid-19 Outbreak in Northern Italy, N. Engl. J. Med. (2020) 1–3.
[15] Bernhard Metzler, Peter Siostrzonek, Ronald K Binder, Axel Bauer, Sebastian
Johannes Reinstadler, Decline of acute coronary syndrome admissions in
Austria since the outbreak of COVID-19: the pandemic response causes cardiac
collateral damage, Eur. Heart J. 41 (19) (2020) 1852–1853, https://doi.org/
10.1093/eurheartj/ehaa314.
[16] Santiago Garcia, Mazen S. Albaghdadi, Perwaiz M. Meraj, Christian Schmidt,
Ross Garberich, Farouc A. Jaffer, Simon Dixon, Jeffrey J. Rade, Mark
Tannenbaum, Jenny Chambers, Paul P. Huang, Timothy D. Henry, Reduction
in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the
United States During COVID-19 Pandemic, Journal of the American College of
Cardiology 75 (22) (2020) 2871–2872, https://doi.org/10.1016/
j.jacc.2020.04.011.
[17] Elsebeth Lynge, Jakob Lynge Sandegaard, Matejka Rebolj, The Danish National
Patient Register, Scand J Public Health 39 (7_suppl) (2011) 30–33, https://doi.
org/10.1177/1403494811401482.
[18] Helle Wallach Kildemoes, Henrik Toft Sørensen, Jesper Hallas, The Danish
National Prescription Registry, Scand J Public Health 39 (7_suppl) (2011) 38–
41, https://doi.org/10.1177/1403494810394717.
[19] Carsten Bøcker Pedersen, The Danish Civil Registration System, Scand J Public
Health 39 (7_suppl) (2011) 22–25, https://doi.org/10.1177/1403494810387965.
[20] Mikkel Baadsgaard, Jarl Quitzau, Danish registers on personal income and
transfer payments, Scand J Public Health 39 (7_suppl) (2011) 103–105, https://
doi.org/10.1177/1403494811405098.
[21] Vibeke M. Jensen, Astrid W. Rasmussen, Danish education registers, Scand J
Public Health 39 (7_suppl) (2011) 91–94, https://doi.org/10.1177/
1403494810394715.
[22] Tina Ken Schramm, Gunnar H. Gislason, Lars Køber, Søren Rasmussen, Jeppe N.
Rasmussen, Steen Z. Abildstrøm, Morten Lock Hansen, Fredrik Folke, Pernille
Buch, Mette Madsen, Allan Vaag, Christian Torp-Pedersen, Diabetes Patients
Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior
Myocardial Infarction Carry the Same Cardiovascular Risk: A Population
Study of 3.3 Million People, Circulation 117 (15) (2008) 1945–1954, https://
doi.org/10.1161/CIRCULATIONAHA.107.720847.
[23] J.B. Olesen, G.Y.H. Lip, M.L. Hansen, P.R. Hansen, J.S. Tolstrup, J. Lindhardsen, C.
Selmer, O. Ahlehoff, A.-M.S. Olsen, G.H. Gislason, C. Torp-Pedersen, Validation
of risk stratification schemes for predicting stroke and thromboembolism in
patients with atrial fibrillation: nationwide cohort study, BMJ 342 (jan31 1)
(2011) d124, https://doi.org/10.1136/bmj.d124.
E. Havers-Borgersen, E.L. Fosbøl, J.H. Butt et al. IJC Heart & Vasculature 31 (2020) 100675[24] L. Østergaard, K. Adelborg, J. Sundbøll, L. Pedersen, E.L. Fosbøl, M. Schmidt,
Positive predictive value of infective endocarditis in the Danish National
Patient Registry: a validation study, BMJ Open. 6 (2018), https://doi.org/
10.1136/bmjopen-2016-012832 e012832.
[25] Lauge Østergaard, Nana Valeur, Nikolaj Ihlemann, Henning Bundgaard, Gunnar
Gislason, Christian Torp-Pedersen, Niels Eske Bruun, Lars Søndergaard, Lars
Køber, Emil Loldrup Fosbøl, Incidence of infective endocarditis among patients
considered at high risk, Eur. Heart J. 39 (7) (2018) 623–629, https://doi.org/
10.1093/eurheartj/ehx682.
[26] Lauge Østergaard, Nana Valeur, Andrew Wang, Henning Bundgaard, Mohsin
Aslam, Gunnar Gislason, Christian Torp-Pedersen, Niels Eske Bruun, Lars
Søndergaard, Lars Køber, Emil Loldrup Fosbøl, Incidence of infective
endocarditis in patients considered at moderate risk, Eur. Heart J. 40 (17)
(2019) 1355–1361, https://doi.org/10.1093/eurheartj/ehy629.7
[27] Sundhedsstyrelsen, Personer med øget risiko ved COVID-19, (2020) 48.
[28] Azhar Hussain, Neil Roberts, Aung Oo, Prosthetic aortic valve endocarditis
complicated by COVID-19 and hemorrhage, J Card Surg 35 (6) (2020) 1348–
1350, https://doi.org/10.1111/jocs.14643.
[29] M.M. Samit Ghosal, Rahul Bhattacharyya, Impact of complete lockdown on
total infection and death rates: A hierarchical cluster analysis, Diabetes Metab.
Syndr. Clin. Res. Rev. (2020).
[30] Jens Sundbøll, Kasper Adelborg, Troels Munch, Trine Frøslev, Henrik Toft
Sørensen, Hans Erik Bøtker, Morten Schmidt, Positive predictive value of
cardiovascular diagnoses in the Danish National Patient Registry: a validation
study, BMJ Open 6 (11) (2016) e012832, https://doi.org/10.1136/bmjopen-
2016-012832.
